Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain undefined. Resistance developed in a patient with metastatic anaplastic thyroid carcinoma after an extraordin...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:N Engl J Med
Egile Nagusiak: Wagle, Nikhil, Grabiner, Brian C., Van Allen, Eliezer M., Amin-Mansour, Ali, Taylor-Weiner, Amaro, Rosenberg, Mara, Gray, Nathanael, Barletta, Justine A., Guo, Yanan, Swanson, Scott J., Ruan, Daniel T., Hanna, Glenn J., Haddad, Robert I., Getz, Gad, Kwiatkowski, David J., Carter, Scott L., Sabatini, David M., Jänne, Pasi A., Garraway, Levi A., Lorch, Jochen H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4564868/
https://ncbi.nlm.nih.gov/pubmed/25295501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1403352
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak